Circulation:老年患者生物瓣和机械瓣置换治疗的长期安全性和有效性

2013-05-03 Circulation dxy

图注:机械瓣和生物瓣患者死亡率(危险因素校正后),主动脉瓣膜置入初,生物瓣治疗患者较机械瓣膜患者再手术风险高。尽管两组总体死亡率相似,超过9年的生物瓣患者相对死亡风险高于机械瓣患者。AV表示主动脉瓣;AVRR表示主动脉瓣修复或置换;Bio代表生物瓣;Mech代表机械瓣。 近年来越来越多老年人接受主动脉瓣置换术治疗,由于机械瓣的血栓风险,生物瓣膜是一个替代选择方案。当前在老年患者中比较生物瓣和机械

图注:机械瓣和生物瓣患者死亡率(危险因素校正后),主动脉瓣膜置入初,生物瓣治疗患者较机械瓣膜患者再手术风险高。尽管两组总体死亡率相似,超过9年的生物瓣患者相对死亡风险高于机械瓣患者。AV表示主动脉瓣;AVRR表示主动脉瓣修复或置换;Bio代表生物瓣;Mech代表机械瓣。

近年来越来越多老年人接受主动脉瓣置换术治疗,由于机械瓣的血栓风险,生物瓣膜是一个替代选择方案。当前在老年患者中比较生物瓣和机械瓣长期安全性和有效性的研究较少,研究人员对美国胸外科医师学会成人心脏病手术数据库(the Society of Thoracic Surgeons Adult Cardiac Surgery Database)的有医疗保险患者进行分析,评价这些机械瓣和生物瓣患者长期死亡率和瓣膜相关并发症情况;并在亚组患者进行进一步分析。

研究人员对其中的1991年至1999年间在605家中心接受主动脉瓣置换术患者(65-80岁)进行随访,其中有24410例患者使用的是生物瓣膜,有14789例患者采用机械瓣。随访平均时间为12.6年(最长17年,最短 8年)。通过倾向性评分方法比较分析两组患者的预后情况。

患者接受主动脉置换术时平均年龄为73岁,12年中需再手术(4.0%)和发生心内膜炎(1.9%)并不常见;但其他不良预后发生较多,包括死亡(66.5%)、卒中(14.1%)和出血(17.9%)。与机械瓣患者相比较,生物瓣患者死亡率相似(校正后,危险比HR=1.04,95% CI 1.01–1.07),再手术(HR=2.55,95% CI 2.14–3.03)和心内膜炎(1.60; 95% CI 1.31–1.94)风险较高,卒中(HR=0.87; 95% CI 0.82–0.93)和出血(HR= 0.66; 95% CI 0.62–0.70)风险较低。

各个亚组分析结果与上述结果大体一致,其中使用生物瓣患者(65-69岁)12年的再次手术绝对风险升高(10.5%)。

研究人员最后指出,接受主动脉瓣置换术的患者,不管是使用生物瓣还是机械瓣,长期死亡率相似。其中,生物瓣患者有较高长期再次手术和心内膜炎风险,但卒中和出血风险较低。

总而言之,人工瓣膜的安全性和有效性很大程度上取决于患者的年龄和合并症情况。研究强调了医生和患者在瓣膜置换前认真讨论和交流的必要性,针对患者个体的不同情况作出合适的选择。

主动脉相关的拓展阅读:


Long-term safety and effectiveness of mechanical versus biologic aortic valve prostheses in older patients: results from the society of thoracic surgeons adult cardiac surgery national database.
BACKGROUND
There is a paucity of long-term data comparing biological versus mechanical aortic valve prostheses in older individuals.
METHODS AND RESULTS
We performed follow-up of patients aged 65 to 80 years undergoing aortic valve replacement with a biological (n=24 410) or mechanical (n=14 789) prosthesis from 1991 to 1999 at 605 centers within the Society of Thoracic Surgeons Adult Cardiac Surgery Database using Medicare inpatient claims (mean, 12.6 years; maximum, 17 years; minimum, 8 years), and outcomes were compared by propensity methods. Among Medicare-linked patients undergoing aortic valve replacement (mean age, 73 years), both reoperation (4.0%) and endocarditis (1.9%) were uncommon to 12 years; however, the risk for other adverse outcomes was high, including death (66.5%), stroke (14.1%), and bleeding (17.9%). Compared with those receiving a mechanical valve, patients given a bioprosthesis had a similar adjusted risk for death (hazard ratio, 1.04; 95% confidence interval, 1.01-1.07), higher risks for reoperation (hazard ratio, 2.55; 95% confidence interval, 2.14-3.03) and endocarditis (hazard ratio, 1.60; 95% confidence interval, 1.31-1.94), and lower risks for stroke (hazard ratio, 0.87; 95% confidence interval, 0.82-0.93) and bleeding (hazard ratio, 0.66; 95% confidence interval, 0.62-0.70). Although these results were generally consistent among patient subgroups, bioprosthesis patients aged 65 to 69 years had a substantially elevated 12-year absolute risk of reoperation (10.5%).
CONCLUSIONS
Among patients undergoing aortic valve replacement, long-term mortality rates were similar for those who received bioprosthetic versus mechanical valves. Bioprostheses were associated with a higher long-term risk of reoperation and endocarditis but a lower risk of stroke and hemorrhage. These risks varied as a function of a patient's age and comorbidities.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2078748, encodeId=c2f320e8748ed, content=<a href='/topic/show?id=a31661265fd' target=_blank style='color:#2F92EE;'>#机械瓣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61265, encryptionId=a31661265fd, topicName=机械瓣)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7db99, createdName=chg121, createdTime=Tue May 07 23:16:00 CST 2013, time=2013-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1742243, encodeId=3b4b1e4224391, content=<a href='/topic/show?id=39cae96626f' target=_blank style='color:#2F92EE;'>#置换#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79662, encryptionId=39cae96626f, topicName=置换)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a7c35056336, createdName=yxch48, createdTime=Tue Nov 12 16:16:00 CST 2013, time=2013-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2066606, encodeId=9a8f206660628, content=<a href='/topic/show?id=1d3d45e090e' target=_blank style='color:#2F92EE;'>#安全性和有效性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45709, encryptionId=1d3d45e090e, topicName=安全性和有效性)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/E33DC517C2EC449E463E3D01D81745BA/100, createdBy=75e12500157, createdName=ms1756883563247400, createdTime=Fri Mar 21 00:16:00 CST 2014, time=2014-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1635538, encodeId=934d163553887, content=<a href='/topic/show?id=83a3693965d' target=_blank style='color:#2F92EE;'>#生物瓣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69396, encryptionId=83a3693965d, topicName=生物瓣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ddce22497218, createdName=396094184_42047362, createdTime=Tue Oct 15 05:16:00 CST 2013, time=2013-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1807315, encodeId=60a9180e3150e, content=<a href='/topic/show?id=d7c2e9666bd' target=_blank style='color:#2F92EE;'>#置换治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79666, encryptionId=d7c2e9666bd, topicName=置换治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sat Jul 13 08:16:00 CST 2013, time=2013-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990261, encodeId=024d199026140, content=<a href='/topic/show?id=abc896996e1' target=_blank style='color:#2F92EE;'>#长期安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96996, encryptionId=abc896996e1, topicName=长期安全性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=65c7309, createdName=fengxx, createdTime=Wed Feb 19 14:16:00 CST 2014, time=2014-02-19, status=1, ipAttribution=)]
    2013-05-07 chg121
  2. [GetPortalCommentsPageByObjectIdResponse(id=2078748, encodeId=c2f320e8748ed, content=<a href='/topic/show?id=a31661265fd' target=_blank style='color:#2F92EE;'>#机械瓣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61265, encryptionId=a31661265fd, topicName=机械瓣)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7db99, createdName=chg121, createdTime=Tue May 07 23:16:00 CST 2013, time=2013-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1742243, encodeId=3b4b1e4224391, content=<a href='/topic/show?id=39cae96626f' target=_blank style='color:#2F92EE;'>#置换#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79662, encryptionId=39cae96626f, topicName=置换)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a7c35056336, createdName=yxch48, createdTime=Tue Nov 12 16:16:00 CST 2013, time=2013-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2066606, encodeId=9a8f206660628, content=<a href='/topic/show?id=1d3d45e090e' target=_blank style='color:#2F92EE;'>#安全性和有效性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45709, encryptionId=1d3d45e090e, topicName=安全性和有效性)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/E33DC517C2EC449E463E3D01D81745BA/100, createdBy=75e12500157, createdName=ms1756883563247400, createdTime=Fri Mar 21 00:16:00 CST 2014, time=2014-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1635538, encodeId=934d163553887, content=<a href='/topic/show?id=83a3693965d' target=_blank style='color:#2F92EE;'>#生物瓣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69396, encryptionId=83a3693965d, topicName=生物瓣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ddce22497218, createdName=396094184_42047362, createdTime=Tue Oct 15 05:16:00 CST 2013, time=2013-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1807315, encodeId=60a9180e3150e, content=<a href='/topic/show?id=d7c2e9666bd' target=_blank style='color:#2F92EE;'>#置换治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79666, encryptionId=d7c2e9666bd, topicName=置换治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sat Jul 13 08:16:00 CST 2013, time=2013-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990261, encodeId=024d199026140, content=<a href='/topic/show?id=abc896996e1' target=_blank style='color:#2F92EE;'>#长期安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96996, encryptionId=abc896996e1, topicName=长期安全性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=65c7309, createdName=fengxx, createdTime=Wed Feb 19 14:16:00 CST 2014, time=2014-02-19, status=1, ipAttribution=)]
    2013-11-12 yxch48
  3. [GetPortalCommentsPageByObjectIdResponse(id=2078748, encodeId=c2f320e8748ed, content=<a href='/topic/show?id=a31661265fd' target=_blank style='color:#2F92EE;'>#机械瓣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61265, encryptionId=a31661265fd, topicName=机械瓣)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7db99, createdName=chg121, createdTime=Tue May 07 23:16:00 CST 2013, time=2013-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1742243, encodeId=3b4b1e4224391, content=<a href='/topic/show?id=39cae96626f' target=_blank style='color:#2F92EE;'>#置换#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79662, encryptionId=39cae96626f, topicName=置换)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a7c35056336, createdName=yxch48, createdTime=Tue Nov 12 16:16:00 CST 2013, time=2013-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2066606, encodeId=9a8f206660628, content=<a href='/topic/show?id=1d3d45e090e' target=_blank style='color:#2F92EE;'>#安全性和有效性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45709, encryptionId=1d3d45e090e, topicName=安全性和有效性)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/E33DC517C2EC449E463E3D01D81745BA/100, createdBy=75e12500157, createdName=ms1756883563247400, createdTime=Fri Mar 21 00:16:00 CST 2014, time=2014-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1635538, encodeId=934d163553887, content=<a href='/topic/show?id=83a3693965d' target=_blank style='color:#2F92EE;'>#生物瓣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69396, encryptionId=83a3693965d, topicName=生物瓣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ddce22497218, createdName=396094184_42047362, createdTime=Tue Oct 15 05:16:00 CST 2013, time=2013-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1807315, encodeId=60a9180e3150e, content=<a href='/topic/show?id=d7c2e9666bd' target=_blank style='color:#2F92EE;'>#置换治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79666, encryptionId=d7c2e9666bd, topicName=置换治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sat Jul 13 08:16:00 CST 2013, time=2013-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990261, encodeId=024d199026140, content=<a href='/topic/show?id=abc896996e1' target=_blank style='color:#2F92EE;'>#长期安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96996, encryptionId=abc896996e1, topicName=长期安全性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=65c7309, createdName=fengxx, createdTime=Wed Feb 19 14:16:00 CST 2014, time=2014-02-19, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2078748, encodeId=c2f320e8748ed, content=<a href='/topic/show?id=a31661265fd' target=_blank style='color:#2F92EE;'>#机械瓣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61265, encryptionId=a31661265fd, topicName=机械瓣)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7db99, createdName=chg121, createdTime=Tue May 07 23:16:00 CST 2013, time=2013-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1742243, encodeId=3b4b1e4224391, content=<a href='/topic/show?id=39cae96626f' target=_blank style='color:#2F92EE;'>#置换#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79662, encryptionId=39cae96626f, topicName=置换)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a7c35056336, createdName=yxch48, createdTime=Tue Nov 12 16:16:00 CST 2013, time=2013-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2066606, encodeId=9a8f206660628, content=<a href='/topic/show?id=1d3d45e090e' target=_blank style='color:#2F92EE;'>#安全性和有效性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45709, encryptionId=1d3d45e090e, topicName=安全性和有效性)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/E33DC517C2EC449E463E3D01D81745BA/100, createdBy=75e12500157, createdName=ms1756883563247400, createdTime=Fri Mar 21 00:16:00 CST 2014, time=2014-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1635538, encodeId=934d163553887, content=<a href='/topic/show?id=83a3693965d' target=_blank style='color:#2F92EE;'>#生物瓣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69396, encryptionId=83a3693965d, topicName=生物瓣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ddce22497218, createdName=396094184_42047362, createdTime=Tue Oct 15 05:16:00 CST 2013, time=2013-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1807315, encodeId=60a9180e3150e, content=<a href='/topic/show?id=d7c2e9666bd' target=_blank style='color:#2F92EE;'>#置换治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79666, encryptionId=d7c2e9666bd, topicName=置换治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sat Jul 13 08:16:00 CST 2013, time=2013-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990261, encodeId=024d199026140, content=<a href='/topic/show?id=abc896996e1' target=_blank style='color:#2F92EE;'>#长期安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96996, encryptionId=abc896996e1, topicName=长期安全性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=65c7309, createdName=fengxx, createdTime=Wed Feb 19 14:16:00 CST 2014, time=2014-02-19, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2078748, encodeId=c2f320e8748ed, content=<a href='/topic/show?id=a31661265fd' target=_blank style='color:#2F92EE;'>#机械瓣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61265, encryptionId=a31661265fd, topicName=机械瓣)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7db99, createdName=chg121, createdTime=Tue May 07 23:16:00 CST 2013, time=2013-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1742243, encodeId=3b4b1e4224391, content=<a href='/topic/show?id=39cae96626f' target=_blank style='color:#2F92EE;'>#置换#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79662, encryptionId=39cae96626f, topicName=置换)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a7c35056336, createdName=yxch48, createdTime=Tue Nov 12 16:16:00 CST 2013, time=2013-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2066606, encodeId=9a8f206660628, content=<a href='/topic/show?id=1d3d45e090e' target=_blank style='color:#2F92EE;'>#安全性和有效性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45709, encryptionId=1d3d45e090e, topicName=安全性和有效性)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/E33DC517C2EC449E463E3D01D81745BA/100, createdBy=75e12500157, createdName=ms1756883563247400, createdTime=Fri Mar 21 00:16:00 CST 2014, time=2014-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1635538, encodeId=934d163553887, content=<a href='/topic/show?id=83a3693965d' target=_blank style='color:#2F92EE;'>#生物瓣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69396, encryptionId=83a3693965d, topicName=生物瓣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ddce22497218, createdName=396094184_42047362, createdTime=Tue Oct 15 05:16:00 CST 2013, time=2013-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1807315, encodeId=60a9180e3150e, content=<a href='/topic/show?id=d7c2e9666bd' target=_blank style='color:#2F92EE;'>#置换治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79666, encryptionId=d7c2e9666bd, topicName=置换治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sat Jul 13 08:16:00 CST 2013, time=2013-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990261, encodeId=024d199026140, content=<a href='/topic/show?id=abc896996e1' target=_blank style='color:#2F92EE;'>#长期安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96996, encryptionId=abc896996e1, topicName=长期安全性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=65c7309, createdName=fengxx, createdTime=Wed Feb 19 14:16:00 CST 2014, time=2014-02-19, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2078748, encodeId=c2f320e8748ed, content=<a href='/topic/show?id=a31661265fd' target=_blank style='color:#2F92EE;'>#机械瓣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61265, encryptionId=a31661265fd, topicName=机械瓣)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7db99, createdName=chg121, createdTime=Tue May 07 23:16:00 CST 2013, time=2013-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1742243, encodeId=3b4b1e4224391, content=<a href='/topic/show?id=39cae96626f' target=_blank style='color:#2F92EE;'>#置换#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79662, encryptionId=39cae96626f, topicName=置换)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a7c35056336, createdName=yxch48, createdTime=Tue Nov 12 16:16:00 CST 2013, time=2013-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2066606, encodeId=9a8f206660628, content=<a href='/topic/show?id=1d3d45e090e' target=_blank style='color:#2F92EE;'>#安全性和有效性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45709, encryptionId=1d3d45e090e, topicName=安全性和有效性)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/E33DC517C2EC449E463E3D01D81745BA/100, createdBy=75e12500157, createdName=ms1756883563247400, createdTime=Fri Mar 21 00:16:00 CST 2014, time=2014-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1635538, encodeId=934d163553887, content=<a href='/topic/show?id=83a3693965d' target=_blank style='color:#2F92EE;'>#生物瓣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69396, encryptionId=83a3693965d, topicName=生物瓣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ddce22497218, createdName=396094184_42047362, createdTime=Tue Oct 15 05:16:00 CST 2013, time=2013-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1807315, encodeId=60a9180e3150e, content=<a href='/topic/show?id=d7c2e9666bd' target=_blank style='color:#2F92EE;'>#置换治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79666, encryptionId=d7c2e9666bd, topicName=置换治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sat Jul 13 08:16:00 CST 2013, time=2013-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990261, encodeId=024d199026140, content=<a href='/topic/show?id=abc896996e1' target=_blank style='color:#2F92EE;'>#长期安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96996, encryptionId=abc896996e1, topicName=长期安全性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=65c7309, createdName=fengxx, createdTime=Wed Feb 19 14:16:00 CST 2014, time=2014-02-19, status=1, ipAttribution=)]

相关资讯

J Clin Psychiatry:4种非典型抗精神病药对老年人缺乏安全性和疗效

       近日一篇刊于《临床精神病学》杂志的文章中,研究者对332例被诊断有精神分裂症、情感障碍、创伤后应激障碍或痴呆相关精神病,且年龄>40岁的患者服用的四种抗精神病药物的安全性和疗效展开调查。结果显示,阿立哌唑( Abilify,大冢公司)、奥氮平(Zyprexa,礼来公司)、喹硫平(Seroquel,阿斯利康公司)和利培酮(Ri

ASCO:老年肾癌等待观察或优于手术

    MedSci点评:近年来其实有不少研究有关“Watch and Wait”(等待观察)而不手术或化疗或放疗的研究,尤其是针对一些低恶性肿瘤,或可疑肿瘤,或高龄患者。这也是临床对肿瘤的治疗思路的升级,这方面研究也是近年来研究热点。期待国内有类似研究成果出现。原始新闻:  一项最新研究显示,有时简单的观察等待策略可取代手术成为小肾脏肿瘤老年患者的安全替代疗法。“医

Oncogene:老年人组织特性改变增加癌症发病率

  癌症与年龄有关,老年人发生癌症比年轻人更频繁。科罗拉多大学癌症中心的研究者们撰写了一篇综述,于7月2日发表在Oncogene杂志上。该文颠覆了由于致癌性突变的积累而导致了老年人罹患肿瘤增多的传统认识,提出了是由于老年人组织特性发生改变而促进了其癌症的发病率增加。   “如果你将1960年的Mick Jagger和今天的他进行比较,可以非常明显的看到他的组织特点发生了改变,”科罗拉多

A&R:老年女性椎间盘间隙狭窄的患病率和严重程度均高于老年男性

椎间盘间隙狭窄是老年人常见的疾病。为研究中国人群中老年人椎间盘狭窄的患病特点,来自香港中文大学和威尔士亲王医院的Yi-Xiang J. Wang博士等人通过一项在老年(>65岁)中国男性(2000例)和中国女性(2000例)的中进行的第一次大规模以人群为基础的骨健康前瞻研究,对香港男性和女性的骨质疏松骨折进行分析。研究者收集并分析这些病例中椎间盘间隙狭窄的患病率,并分析性别、骨密度(BMD)

Hypertension:黄烷醇可改善老年认知功能(CoCoA研究)

8月14日,在线发表于《高血压》杂志(Hypertension)的意大利一项研究显示,有规律地通过膳食补充可可黄烷醇可能会提高老年轻度认知障碍患者的认知功能,且这种作用可能部分受胰岛素敏感性提高影响。 纳入研究的90例患有轻度认知功能障碍的老年患者被随机分为3组,分别通过饮食补充高含量(≈990 mg)、中等含量(≈520 mg)和低含量(≈45 mg)的黄烷醇饮品,每天一次,共8周。随访发现,

BMC Cancer:糖尿病恶化乳腺癌患者预后

  《生物医学中心癌症》(BMC Cancer)杂志2012年12月26日在线发表的一项研究指出,既往未诊断出糖尿病的老年乳腺癌患者,其临床分期和死亡率更高。   该研究是一项基于Seer-medicare数据库的观察性队列研究。研究者利用来自Surveillance、Epidemiology和End Results-Medicare linked dat